GlassScriptPhysician profile
Jessica Bridgforth
NPI 1497305262
$8,281.37
in general payments reported to CMS, 2019-2025
21 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,516 · 2022: $2,022 · 2023: $1,856 · 2024: $1,524 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,074.67 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,374.40 | 2021-2025 | |
| Janssen Biotech, INC. | $922.43 | 2021-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $879.01 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $629.72 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $447.78 | 2021-2024 | Linzess |
| Qol Medical, LLC | $439.02 | 2021-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $340.71 | 2025 | Voquezna |
| Genzyme Corporation | $250.51 | 2022-2025 | |
| Ardelyx, INC. | $245.30 | 2024-2025 | Ibsrela |
| Pfizer INC. | $149.64 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $124.97 | 2024 | Nuzyra |
| Intercept Pharmaceuticals, INC. | $102.74 | 2021-2025 | Ocaliva |
| Celgene Corporation | $86.93 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $69.27 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.15 | 2021-2023 | Dificid |
| Alnylam Pharmaceuticals INC. | $26.63 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.38 | 2024 | Dupixent |
| Amgen INC. | $17.96 | 2022 | |
| Braintree Laboratories, INC. | $17.08 | 2022 | |
| Madrigal Pharmaceuticals | $15.07 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Bridgforth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.